Brief: Silence Therapeutics Announces Positive 36-Week Data From Ongoing Phase 2 Study Of Zerlasiran In Patients With High Lipoprotein(A)

Silence Therapeutics

13/03/2024 12:39

March 13 (Reuters) - Silence Therapeutics PLC
 SLNCF.PK :
    * SILENCE THERAPEUTICS PLC: STUDY MET PRIMARY ENDPOINT AND
DEMONSTRATED HIGHLY SIGNIFICANT REDUCTIONS IN LP(A) TO WEEK 36
    * SILENCE THERAPEUTICS PLC: LIPOPROTEIN(A) REDUCTION WAS
CONSISTENT WITH PHASE 1 RESULTS
    * SILENCE THERAPEUTICS PLC: TOPLINE 48-WEEK DATA EXPECTED IN
2Q
2024
    * SILENCE THERAPEUTICS ANNOUNCES POSITIVE TOPLINE 36-WEEK
DATA
FROM ONGOING PHASE 2 STUDY OF ZERLASIRAN IN PATIENTS WITH HIGH
LIPOPROTEIN(A)

Source text for Eikon:  ID:nBw8jkRy7a 
Further company coverage:  SLNCF.PK 

 ((Reuters.Briefs@thomsonreuters.com;))